The local subsidiary of Danish diabetes care giant Novo Nordisk (NOV: N), the sponsor of semaglutide (Ozempic) solution for injection pre-filled pen, notified the Australian Therapeutic Goods Administration (TGA) of a shortage of both strengths of semaglutide (Ozempic ) products due to an unexpected increase in consumer demand.
The increased demand is due to extensive prescribing of the drug for obesity management, for which Ozempic is not indicated.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Try before you buy
• All the news that moves the needle in pharma and biotech.
• Exclusive features, podcasts, interviews, data analyzes and commentary from our global network of life sciences reporters.
• Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
• Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
• Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
• Daily roundup of key events in pharma and biotech.
• Monthly in-depth briefings on Boardroom appointments and M&A news.
• Choose from a cost-effective annual package or a flexible monthly subscription.